阿得贝利单抗(Adebrelimab) - 药物靶点：PDL1_在研适应症：广泛期小细胞肺癌，非小细胞肺癌，晚期胆道癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

HTI-1088、HTI-1316、SHR 1316

+ [2]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤呼吸系统疾病消化系统疾病+ [6]

在研适应症

广泛期小细胞肺癌非小细胞肺癌晚期胆道癌+ [55]

非在研适应症

晚期食管鳞状细胞癌HR阳性/HER2低表达实体瘤复发性小细胞肺癌

原研机构

在研机构

+ [2]

非在研机构

Atridia Pty Ltd.

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2023-02-28),

广泛期小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (中国)、特殊审批 (中国)

登录后查看时间轴

结构/序列

Sequence Code 13388064H

来源: *****

Sequence Code 13388069L

来源: *****

关联

382

项与阿得贝利单抗相关的临床试验

ChiCTR2600119287

/ Not yet recruitingN/AIIT

Cryoablation followed by adebrelimab and chemotherapy for oligoprogressive NSCLC after first-line immunotherapy: A single-center, single-arm, phase II clinical study

开始日期2026-03-01

申办/合作机构-

ChiCTR2600118795

/ Not yet recruiting临床4期IIT

A Single-Arm, Single-Center, Phase II Clinical Study of Neoadjuvant Therapy with Sacituzumab Tirumotecan Combined with Adebrelimab in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

开始日期2026-02-24

申办/合作机构-

NCT07388095

/ Not yet recruitingN/AIIT

Neoadjuvant Treatment With Adebrelimab in Combination With Nimotuzumab and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Single-arm, Exploratory Phase II Clinical Study

This is a prospective, phase II, exploratory clinical trial.
The study aims to evaluate the efficacy and safety of in combination adebrelimab with nimotuzumab and chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma.
The primary endpoint is pCR ( pathological complete response), evaluating the efficacy of adebrelimab in combination with nimotuzumab and neoadjuvant chemotherapy in patients with resectable esophageal squamous cell carcinoma. After the primary objective is achieved, EFS (event free survival ), R0 resection rate, MPR (major pathological response), OS (overall survival), and safety will be assessed as key secondary objectives. The study plans to enroll 22 patients with resectable esophageal squamous cell carcinoma.
The study is divided into a screening period, a treatment period, and a follow-up period. Subjects will enter the screening period after signing informed consent. Subjects who pass the screening assessment will be enrolled in the study. Eligible subjects will receive two cycles of neoadjuvant therapy with adebrelimab, nimotuzumab, nab-paclitaxel, and cisplatin. Esophagectomy will be performed after two cycles of neoadjuvant therapy (4-6 weeks after the last dose). Researchers will determine subsequent treatment based on postoperative pathology. After treatment (surgery), safety and efficacy follow-ups will commence. When a subject first experiences disease progression as assessed by the investigator according to RECIST v1.1, confirmation is required after 4-6 weeks (except for rapid or significant clinical progression). Subjects whose disease progression is not confirmed by imaging after 4-6 weeks may continue treatment if their clinical symptoms remain stable, as determined by the investigator, until imaging-confirmed disease progression occurs, or other termination criteria as specified in the protocol are met, whichever occurs first.

开始日期2026-02-15

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

100 项与阿得贝利单抗相关的临床结果

登录后查看更多信息

100 项与阿得贝利单抗相关的转化医学

登录后查看更多信息

100 项与阿得贝利单抗相关的专利（医药）

登录后查看更多信息

36

项与阿得贝利单抗相关的文献（医药）

2026-02-01·BMJ Open

Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial

Article

作者: Cheng, Yuan ; Chi, Yongquan ; Cheng, Feng ; Rao, Jianhua ; Xia, Jinguo

Introduction:

Intrahepatic cholangiocarcinoma (ICC) has a high recurrence rate after curative surgery, with no standard neoadjuvant therapy. Hepatic arterial infusion chemotherapy (HAIC) has shown efficacy in locally advanced ICC, while immune checkpoint inhibitors and anti-angiogenic agents have demonstrated promising response rates. The NEO-ERA-01 study evaluates the feasibility of neoadjuvant HAIC-GEMOX plus lenvatinib and Adebrelimab in high-risk resectable ICC.

Methods and analysis:

NEO-ERA-01 is a prospective, multicentre, phase II trial using Simon’s two-stage design. Thirty patients with histologically confirmed resectable ICC and high-risk recurrence factors will be enrolled in China. Neoadjuvant therapy consists of HAIC-GEMOX (gemcitabine 800 mg/m², oxaliplatin 85 mg/m² every 3 weeks), lenvatinib (8 mg/day from Day 5) and Adebrelimab (1200 mg on Day 3, every 3 weeks) for 2–4 cycles. Surgery eligibility will be assessed post-treatment. Resected patients will receive adjuvant capecitabine (1250 mg/m² two times per day on Days 1–14, every 3 weeks) and Adebrelimab (1200 mg on Day 1, every 3 weeks) for 6 months.The primary endpoint is the completion rate of study treatment. Secondary endpoints include safety, R0 resection rate, response rate, event-free survival, disease-free survival and overall survival. Exploratory endpoints include immune microenvironment and biomarker analysis.

Ethics and dissemination:

The study is approved by the ethics committee of all sites and follows the Declaration of Helsinki and good clinical practice guidelines. Results will be disseminated via peer-reviewed publications and conferences.

Trial registration number:

NCT06208462 .

2026-01-01·NEOPLASMA

Efficacy and safety of adebrelimab plus bevacizumab in combination with hepatic artery infusion chemotherapy for advanced stage hepatocellular carcinoma: a retrospective cohort study

Article

作者: Pan, Jiayu ; Nuerhashi, Gulijiayina ; Zheng, Guanglei ; Lin, Letao ; Wang, Yujia ; Wen, Chunyong ; Tang, Ruizhi ; Li, Chen ; Chen, Shuanggang ; Tan, Hongtong ; Fan, Weijun ; Shen, Lujun

Hepatic arterial infusion chemotherapy using a combination of oxaliplatin, fluorouracil, and leucovorin (HAIC-FOLFOX) has shown promise for patients with advanced-stage hepatocellular carcinoma (HCC). In this study, we aim to evaluate the efficacy and safety of combining adebrelimab (anti-PD-L1 antibody) and bevacizumab with HAIC-FOLFOX for HCC patients in BCLC stage C. This retrospective study included 32 untreated advanced-stage HCC patients receiving HAIC-FOLFOX combined with adebrelimab and bevacizumab as first-line therapy. The primary endpoint is overall response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. From January 14th, 2024, to December 5th, 2024, a total of 32 patients received the triplet combination of HAIC-FOLFOX, adebrelimab, and bevacizumab. Median follow-up time was 6.1 months. According to RECIST v1.1 criteria, the confirmed ORR was 71.8% (95% CI: 55.4-88.3%), with a disease control rate (DCR) of 93.7% (95% CI: 84.9-99.9%). Only one case (3.1%) had a grade 3 treatment-related adverse event (rash), which could be alleviated after symptomatic management. The combination of adebrelimab, bevacizumab, and HAIC-FOLFOX demonstrated encouraging results and manageable safety concerns for patients with HCC at BCLC stage C.

2025-11-01·International Journal of Surgery

Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial

Article

作者: Wang, Yan ; Li, Wenhao ; Wang, Yuepeng ; Cai, Yongkang ; Guo, Junhong ; Kang, Ziqin ; Fang, Songling ; Huang, Zhiquan ; Zhuang, Xiumei ; Wen, Zuozhen ; Huang, Zixian ; He, Yilin

Background::

This study aimed to investigate the efficacy of a PD-L1 inhibitor combined with chemotherapy in the treatment of locally advanced oral squamous cell carcinoma (OSCC).

Materials and Methods::

This study was designed as a single-arm phase II trial, and a total of 30 patients were enrolled. All patients were pathologically confirmed to have head and neck squamous cell carcinoma. Patients received paclitaxel, carboplatin, and adebrelimab every 3 weeks as a treatment cycle, followed by surgery after three cycles of treatment. The primary endpoint was the postoperative pathological complete response (PCR) rate. The secondary endpoints included the objective response rate (ORR), major pathological response (MPR) rate, 2-year disease-free survival rate, and 2-year and 5-year overall survival rates. This study was conducted without using artificial intelligence (AI) tools in accordance with the TITAN Guidelines 2025.

Results::

Among the 30 patients, 28 completed the full three cycles of immunochemotherapy, with an ORR of 60.7%. One patient dropped out, and one patient (3.3%) experienced grade 3–4 adverse reactions, leading to discontinuation after the first cycle. In the per-protocol population, 10 patients (35.7%) achieved a PCR in both the primary lesion and lymph nodes, whereas 18 patients (64.3%), including those with a PCR, achieved a MPR. Additionally, 20 patients (71.4%) achieved clinical to pathological downstaging. Common adverse reactions included alopecia (30; 100%), fatigue (7; 23.3%), anemia (24; 80%), hyperthyroidism (2; 6.7%), and pruritus (5; 16.7%).

Conclusions::

Preoperative neoadjuvant immunochemotherapy effectively improved the PCR rate in patients with locally advanced OSCC. PD-L1 inhibitors combined with chemotherapy have promising preliminary efficacy in patients with resectable locally advanced OSCC. However, additional follow-up is needed to obtain more comprehensive survival data and further validate these initial observations.

723

项与阿得贝利单抗相关的新闻（医药）

2026-02-24

·谈医说药

2026年02月24日药品临床试验默示许可

序号受理号药品名称申请人名称适应症注册分类 1 JXSB2500146 ABBV-400注射用粉末 AbbVie Inc. 难治性转移性结直肠癌 1 2 JXHB2500165 Lazertinib片 Janssen Research & Development, LLC 非小细胞肺癌 2.4 3 CXHB2500317 BGM0504注射液博瑞制药（苏州）有限公司本品拟用于1）2型糖尿病；2）超重或肥胖症的治疗。 1 4 CXHB2500316 BGM0504注射液博瑞制药（苏州）有限公司本品拟用于1）2型糖尿病；2）超重或肥胖症的治疗。 1 5 CXHB2500315 BGM0504注射液博瑞制药（苏州）有限公司本品拟用于1）2型糖尿病；2）超重或肥胖症的治疗。 1 6 CXHB2500314 BGM0504注射液博瑞制药（苏州）有限公司本品拟用于1）2型糖尿病；2）超重或肥胖症的治疗。 1 7 CXSB2600013 AZD0901 阿斯利康全球研发（中国）有限公司胃或食管胃结合部腺癌 1 8 CXHL2501408 芦沃美替尼片上海复星医药产业发展有限公司;凯莱英生命科学技术（天津）有限公司本品联合安罗替尼用于治疗至少接受过一种系统性治疗的鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC）成人患者。 2.4 9 CXHL2501407 芦沃美替尼片上海复星医药产业发展有限公司;凯莱英生命科学技术（天津）有限公司本品联合安罗替尼用于治疗至少接受过一种系统性治疗的鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC）成人患者。 2.4 10 CXSL2501086 Pumitamig注射液百时美施贵宝（中国）投资有限公司;百欧恩泰（上海）医药有限公司晚期或不可切除的肝细胞癌的一线治疗。 1 11 CXSL2501078 注射用SHR-9803 江苏恒瑞医药股份有限公司;上海迈晋生物医药科技有限公司本品联合阿得贝利单抗±贝伐珠单抗±化疗治疗实体瘤 1 12 CXSL2501079 帕博利珠单抗注射液华兰基因工程有限公司黑色素瘤、非小细胞肺癌、食管癌、头颈部鳞状细胞癌、结直肠癌、肝细胞癌、胆道癌、三阴性乳腺癌、微卫星高度不稳定型或错配修复基因缺陷型肿瘤、胃癌、宫颈癌、尿路上皮癌。 3.3 13 CXHL2501388 RNK08954片珃诺生物医药科技（杭州）有限公司拟联合化疗或西妥昔单抗±化疗或尼妥珠单抗±化疗用于KRAS G12D突变晚期实体瘤。 1 14 CXSL2501080 GB19注射液深圳科兴药业有限公司系统性红斑狼疮（SLE） 1 15 CXHB2500329 QLS12010胶囊上海齐鲁制药研究中心有限公司拟用于特应性皮炎、化脓性汗腺炎、类风湿关节炎 1 16 CXHL2501382 NS-136片纽欧申医药（上海）有限公司阿尔茨海默病相关激越 1 17 CXHL2501381 NS-136片纽欧申医药（上海）有限公司阿尔茨海默病相关激越 1 18 CXSL2501073 FS-8002注射液上海菩莳医药科技有限公司本品联合化疗或特瑞普利单抗±化疗用于恶性实体瘤。 1 19 CXSL2501071 SHR-2524注射液苏州盛迪亚生物医药有限公司肝细胞癌 2.1;2.3 20 CXSL2501070 SHR-2524注射液苏州盛迪亚生物医药有限公司肝细胞癌 2.1;2.3 21 CXSL2600088 SPX-303注射液科霸生物（江苏）有限公司用于治疗晚期或难治性实体瘤 1 22 CXHL2501397 GenSci141软膏长春金赛药业有限责任公司用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 2.2;2.4 23 CXHL2501396 GenSci141软膏长春金赛药业有限责任公司用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 2.2;2.4 24 CXHL2501395 GenSci141软膏长春金赛药业有限责任公司用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 2.2;2.4 25 CXHL2501394 GenSci141软膏长春金赛药业有限责任公司用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 2.2;2.4 26 CXSL2501074 SM17单克隆抗体注射液（皮下注射）杏联药业（苏州）有限公司炎症性肠病 1 27 CXSB2500236 OCUL101注射液深圳欧科健生物医药科技有限公司继发于年龄相关性黄斑变性的地图样萎缩 1 28 CXSB2500235 OCUL101注射液深圳欧科健生物医药科技有限公司糖尿病性黄斑水肿 1 29 CXSB2500234 OCUL101注射液深圳欧科健生物医药科技有限公司新生血管性年龄相关性黄斑变性 1

2026-02-24

·东方资讯

艾维达HER2 突变非小细胞肺癌一线治疗获突破性治疗认定

近日，恒瑞医药子公司苏州盛迪亚生物医药有限公司自主研发的以HER2为靶点的抗体偶联药物（ADC）创新药注射用瑞康曲妥珠单抗被国家药品监督管理局药品审评中心纳入突破性治疗品种公示名单，适应症为瑞康曲妥珠单抗用于HER2（ERBB2）激活突变的局部晚期或转移性非小细胞肺癌患者的一线治疗。这是瑞康曲妥珠单抗第10次纳入突破性治疗品种名单，充分体现了该药物在多个治疗领域的临床潜力。此前，瑞康曲妥珠单抗已被纳入突破性治疗品种名单的九项适应症为：人表皮生长因子受体2 （HER2）低表达的复发或转移性乳腺癌;HER2阳性的复发或转移性乳腺癌;既往含铂化疗失败的HER2突变的晚期非小细胞肺癌;既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败、HER2阳性结直肠癌;既往至少一线抗HER2治疗失败的HER2阳性晚期胃癌或胃食管结合部腺癌;既往接受过一种或一种以上治疗方案的HER2阳性不可切除或转移性胆道癌;HER2表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌;既往接受含铂化疗及免疫检查点抑制剂治疗失败的HER2表达（IHC≥1+）的复发或转移性宫颈癌;联合阿得贝利单抗用于PD-L1阳性（CPS≥1）局部复发不可切除或转移性三阴性乳腺癌的一线治疗。原发性肺癌是世界范围内最常见的恶性肿瘤。根据GLOBOCAN 2022数据，肺癌发病率和死亡率均居恶性肿瘤首位，全球每年新发肺癌病例数约为248万例，死亡病例数约为182万例，位肿瘤致死病因第一位。2022年中国肺癌新发病例106万例，占全部恶性肿瘤的22.0%;死亡73.33万例，占全部恶性肿瘤死亡的28.5%，在男、女恶性肿瘤发病和死亡顺位中均位居首位。非小细胞肺癌（NSCLC）大约占肺癌的85%，其中约2%–4%的NSCLC患者会发生HER2突变，这一突变与肿瘤侵袭性高、患者预后不良密切相关。近年来，抗体偶联药物及高选择性HER2-TKI在HER2突变晚期NSCLC的后线治疗中取得了重大突破，为该类患者提供了新的治疗选择。目前，初治HER2突变患者的标准治疗方案仍参照驱动基因阴性患者，采用化疗±免疫治疗;针对此类患者的靶向HER2的药物尚未获批，这也成为该领域临床治疗亟待突破的关键瓶颈。注射用瑞康曲妥珠单抗是恒瑞医药自主研发的以HER2为靶点的ADC，可通过与HER2表达的肿瘤细胞结合并内吞，在肿瘤细胞溶酶体内通过蛋白酶剪切释放毒素，诱导细胞周期阻滞从而诱导肿瘤细胞凋亡。其释放的毒素具有高透膜性，可发挥旁观者杀伤效应，进一步提高抗肿瘤疗效。注射用瑞康曲妥珠单抗（商品名：艾维达®）已于2025年5月获批上市，适应症为用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者，是国内首个获批用于HER2突变NSCLC患者的中国自主研发ADC。此外，多项瑞康曲妥珠单抗临床研究正在进行，涵盖非小细胞肺癌、乳腺癌、胃或胃食管结合部腺癌、结直肠癌、胆道癌、妇科恶性肿瘤等。目前，公司已构建包括ADC在内的自有技术平台体系，基于DXh技术的ADC平台已在全球5个主要国家、15个以上瘤种的逾5000例患者中获得验证，目前已有超10种差异化ADC分子成功获批临床。截至2025年11月，恒瑞医药已有1款ADC产品（瑞康曲妥珠单抗，艾维达®）于国内获批上市，4个重点ADC分子处于临床Ⅲ期，还有多个创新药产品布局各个实体肿瘤治疗领域。责任编辑：李震

2026-02-24

·百度百家

艾维达纳入突破性治疗品种公示，助力HER2 突变NSCLC一线治疗

近日,恒瑞医药子公司苏州盛迪亚生物医药有限公司自主研发的以HER2为靶点的抗体偶联药物(ADC)创新药注射用瑞康曲妥珠单抗被国家药品监督管理局药品审评中心纳入突破性治疗品种公示名单,适应症为瑞康曲妥珠单抗用于HER2(ERBB2)激活突变的局部晚期或转移性非小细胞肺癌患者的一线治疗。这是瑞康曲妥珠单抗第10次纳入突破性治疗品种名单,充分体现了该药物在多个治疗领域的临床潜力。　　此前,瑞康曲妥珠单抗已被纳入突破性治疗品种名单的九项适应症为: 　　● 人表皮生长因子受体2 (HER2)低表达的复发或转移性乳腺癌; 　　● HER2阳性的复发或转移性乳腺癌; 　　● 既往含铂化疗失败的HER2突变的晚期非小细胞肺癌; 　　● 既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败、HER2阳性结直肠癌; 　　● 既往至少一线抗HER2治疗失败的HER2阳性晚期胃癌或胃食管结合部腺癌; 　　● 既往接受过一种或一种以上治疗方案的HER2阳性不可切除或转移性胆道癌; 　　● HER2表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌; 　　● 既往接受含铂化疗及免疫检查点抑制剂治疗失败的HER2表达(IHC≥1+)的复发或转移性宫颈癌; 　　● 联合阿得贝利单抗用于PD-L1阳性(CPS≥1)局部复发不可切除或转移性三阴性乳腺癌的一线治疗。　　原发性肺癌是世界范围内最常见的恶性肿瘤。根据GLOBOCAN 2022数据[1],肺癌发病率和死亡率均居恶性肿瘤首位,全球每年新发肺癌病例数约为248万例,死亡病例数约为182万例,位列肿瘤致死病因第一位。2022年中国肺癌新发病例106万例[2],占全部恶性肿瘤的22.0%;死亡73.33万例,占全部恶性肿瘤死亡的28.5%,在男、女恶性肿瘤发病和死亡顺位中均位居首位。　　非小细胞肺癌(NSCLC)大约占肺癌的85%,其中约2%–4%的NSCLC患者会发生HER2突变,这一突变与肿瘤侵袭性高、患者预后不良密切相关[3]。近年来,抗体偶联药物及高选择性HER2-TKI在HER2突变晚期NSCLC的后线治疗中取得了重大突破[4],为该类患者提供了新的治疗选择。目前,初治HER2突变患者的标准治疗方案仍参照驱动基因阴性患者,采用化疗±免疫治疗;针对此类患者的靶向HER2的药物尚未获批,这也成为该领域临床治疗亟待突破的关键瓶颈。　　注射用瑞康曲妥珠单抗是恒瑞医药自主研发的以HER2为靶点的ADC,可通过与HER2表达的肿瘤细胞结合并内吞,在肿瘤细胞溶酶体内通过蛋白酶剪切释放毒素,诱导细胞周期阻滞从而诱导肿瘤细胞凋亡。其释放的毒素具有高透膜性,可发挥旁观者杀伤效应,进一步提高抗肿瘤疗效。注射用瑞康曲妥珠单抗(商品名:艾维达®)已于2025年5月获批上市,适应症为用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者,是国内首个获批用于HER2突变NSCLC患者的中国自主研发ADC。此外,多项瑞康曲妥珠单抗临床研究正在进行,涵盖非小细胞肺癌、乳腺癌、胃或胃食管结合部腺癌、结直肠癌、胆道癌、妇科恶性肿瘤等。　　目前,公司已构建包括ADC在内的自有技术平台体系,基于DXh技术的ADC平台已在全球5个主要国家、15个以上瘤种的逾5000例患者中获得验证,目前已有超10种差异化ADC分子成功获批临床。截至2025年11月,恒瑞医药已有1款ADC产品(瑞康曲妥珠单抗,艾维达®)于国内获批上市,4个重点ADC分子处于临床Ⅲ期,还有多个创新药产品布局各个实体肿瘤治疗领域。来源：生活头条网声明：转载此文是出于传递更多信息之目的。若有来源标注错误或侵犯了您的合法权益，请作者持权属证明与本网联系，我们将及时更正、删除，谢谢。邮箱地址：ahhfxmt@foxmail.com

抗体药物偶联物突破性疗法临床结果临床研究

100 项与阿得贝利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16412

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
广泛期小细胞肺癌	中国	上海盛迪医药有限公司	2023-02-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌	申请上市	中国	上海盛迪医药有限公司	2025-09-23
非小细胞肺癌	申请上市	中国	苏州盛迪亚生物医药有限公司	2025-09-23
晚期胆道癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2026-01-21
晚期宫颈癌	临床3期	中国	上海盛迪医药有限公司	2025-10-17
局部晚期宫颈癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2025-10-17
局部晚期宫颈癌	临床3期	中国	上海盛迪医药有限公司	2025-10-17
PD-L1阳性三阴性乳腺癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2025-08-20
转移性胃食管结合部腺癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2025-08-18
肌层浸润性膀胱癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2025-04-25
晚期肝细胞癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2024-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ChiCTR2400082697 (ASCO_GI2026)	临床2期	局部晚期胃食管交界处腺癌 \| 局部进展期胃腺癌新辅助	11	Adebrelimab + SOX + nab-paclitaxel	壓夢繭積壓廠遞廠範蓋(壓鹹構糧範遞簾蓋蓋顧) = 鑰願醖築製簾選糧範壓膚築艱範選觸淵壓憲壓 (顧獵襯繭齋壓選夢廠壓 ) 更多	积极	2026-01-08
NCT06508229 (ASCO_GI2026)	临床2期	食管鳞状细胞癌新辅助	17	Adebrelimab + Albumin-paclitaxel + Nedaplatin	淵廠遞網鹽鏇顧鹹蓋繭(鏇顧鬱餘獵鹽網簾餘觸) = 鑰鑰淵憲鏇築範鑰糧膚廠獵廠製艱襯糧淵鏇鏇 (願糧繭鹹淵餘顧簾獵鹹 ) 更多	积极	2026-01-08
NCT06389500 (ESMO_ASIA2025)	临床2期	胆道癌	30	HAIC combined with adebrelimab and lenvatinib	鏇醖鬱觸鹹蓋夢觸淵網(積鬱衊淵艱顧襯襯衊窪) = 顧網獵窪蓋糧簾襯壓顧範製鏇鹹簾遞鬱鑰範鬱 (鑰網遞衊憲蓋願築衊艱 ) 更多	积极	2025-12-05
NCT06192186 (ASOG-01, ESMO_ASIA2025)	临床2期	局部进展期胃腺癌新辅助	110	Adebrelimab+SOX	積齋夢選糧顧餘繭鑰餘(窪選醖鏇繭鬱鏇繭繭鹽) = 窪膚製餘鹽觸鹹遞餘襯鬱鹹艱衊艱醖糧壓築積 (選壓遞窪廠齋醖鏇醖鹹 ) 更多	积极	2025-12-05
NCT06192186 (ASOG-01, ESMO_ASIA2025)	临床2期	局部进展期胃腺癌新辅助	110	Placebo+SOX	積齋夢選糧顧餘繭鑰餘(窪選醖鏇繭鬱鏇繭繭鹽) = 窪襯範艱膚壓積築醖範鬱鹹艱衊艱醖糧壓築積 (選壓遞窪廠齋醖鏇醖鹹 ) 更多	积极	2025-12-05
ChiCTR2400082697 (ESMO_ASIA2025)	临床2期	局部进展期胃腺癌 \| 胃食管交界处腺癌新辅助	51	Adebrelimab + SOX + Nab-paclitaxel	壓鬱顧鹽範積襯選淵壓(壓糧顧選艱繭蓋憲夢蓋) = The most common treatment-related adverse events were anemia (34.0%, mainly grade 1 or 2), nausea (22.0%, mainly grade 1), neutropenia (22.0%, mainly grade 1 or 2), and diarrhea (19.0%, mainly grade 1). 積艱遞選醖遞齋觸觸窪 (壓願膚齋願範製簾艱願 )	积极	2025-12-05
ChiCTR2100052533 (ESMO_ASIA2025)	临床2期	广泛期小细胞肺癌末线	25	Adebrelimab+famitinib	鹽蓋齋鹽鬱製淵獵膚醖(築鹹夢壓憲鹽簾觸膚蓋) = 鏇鏇壓願範簾糧蓋齋鏇窪糧觸範積築窪鏇築鬱 (醖餘觸夢襯積獵顧網觸 ) 更多	积极	2025-12-05
ChiCTR2100052533 (ESMO_ASIA2025)	临床2期	广泛期小细胞肺癌末线	25	Adebrelimab+famitinib (2 prior therapy lines)	廠蓋繭餘製壓膚窪膚憲(襯繭齋繭艱製獵醖觸膚) = 餘鬱繭襯蓋鏇遞選壓製鏇積簾選淵鏇鹽鏇製蓋 (構範憲膚鬱網夢淵製淵, 12.5 ~ NA)	积极	2025-12-05
NCT06339216 (ESMO_ASIA2025)	临床2期	晚期胃癌二线	30	ApatinibAdebrelimabnab-Paclitaxel + ApatinibAdebrelimabnab-Paclitaxel + ApatinibAdebrelimabnab-Paclitaxel	廠醖網觸願夢淵構壓鏇(憲製範夢鑰餘憲淵範積) = 願積襯範獵鏇繭窪築齋壓蓋糧艱鹽範繭範襯遞 (糧襯範製鏇遞膚簾鑰艱 ) 更多	积极	2025-12-05
NCT06475417 (ESMO2025) 人工标引	临床2期	局部晚期胃食管交界处腺癌 \| 胃癌新辅助	27	Adebrelimab + docetaxel+oxaliplatin+S-1	窪獵選窪鹽膚遞選夢網(膚網築鹹夢夢鑰製簾獵) = 鑰壓製艱憲鹹構餘選積衊築廠製製築選鬱願積 (憲繭憲餘壓願淵窪窪構 ) 更多	积极	2025-10-17
NCT06475417 (ESMO2025) 人工标引	临床2期	局部晚期胃食管交界处腺癌 \| 胃癌新辅助	27	Adebrelimab +docetaxel+oxaliplatin+S-1 (patients underwent serial ctDNA monitoring)	憲襯築簾窪鬱壓窪繭範(製餘鏇顧構壓鹹餘鬱襯) = 餘蓋憲鹽壓築製鹽遞廠選築鏇網齋構鹽鏇觸鬱 (衊願構築艱鏇製築鬱鬱 ) 更多	积极	2025-10-17
NCT06251492 (RAPID, ESMO2025)	临床2期	转移性去势抵抗性前列腺癌	30	SBRT+adebrelimab (mCRPC)	製獵鏇窪願築觸簾蓋淵(網鏇鹹壓淵願網鑰醖願) = 憲選鏇艱襯糧鏇齋憲糧衊醖觸壓範遞繭網壓鬱 (鑰範鬱齋鑰齋遞製蓋簾, 34.7 ~ 70.8) 更多	积极	2025-10-17
ChiCTR2300079126 (BRAIN-AF01, ESMO2025)	临床2期	PD-L1阳性肺癌一线 PD-L1 ≥50%	11	Adebrelimab 1200 mg IV Q3W with either famitinib or bevacizumab	鬱範鑰餘積淵廠觸醖鑰(願願淵艱選鬱鑰鏇積網) = 膚製壓壓膚醖艱鑰觸鹽艱鏇製夢廠壓襯壓淵醖 (廠範夢簾獵觸網鹹夢觸 ) 更多	积极	2025-10-17